<PAGE>

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-KSB

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the Fiscal Year Ended December 31, 2002

                                       OR

[ ]  TRANSITIONAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 (No Fee Required)

                          Commission File No. 333-45774

                                   Hunapu Inc.
                                   -----------
                 (Name of Small Business Issuer in its Charter)

             Nevada                                         88-0462762
State or other jurisdiction of                            I.R.S. Employer
incorporation or organization                          Identification Number

P.O. Box 50464, Henderson, Nevada                                 89016
Address of principal executive office                           Zip Code

Issuer's telephone number:  (702) 492-9730

SECURITIES REGISTERED PURSUANT TO SECTION 15(d) OF THE ACT

                         Common Stock, $0.001 Par Value
                         ------------------------------
                                (Title of Class)

Check whether the issuer: (1) filed all reports required by Section 13 or 15(d)
of the Exchange Act during the past 12 months, and (2) has been subject to such
filing requirements for the past ninety (90) days.
Yes  X    No
    ---     ---

Check if there is no disclosure of delinquent filers in response to Item 405 of
regulation S-B contained in this form, and no disclosure will be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of the Form 10-KSB or any
amendment to this Form 10-KSB.  X
                               ---
The Company's revenues for Fiscal Year ended December 31, 2002 were $0.00.

As of March 21, 2003, 14,500,000 shares of Common Stock were outstanding and
there was no trading market for the Common Stock. The Number of shares held by
non-affiliates was 2,660,000 shares.

Transitional Small Business Disclosure Format (check one):    Yes       No X
                                                                 ---      ---

                       DOCUMENTS INCORPORATED BY REFERENCE
                                      None.


<PAGE>

                                     PART I

Item 1.  Description of Business.

         Hunapu Inc. (the "Company" or "we" or "us") was incorporated in Nevada
on January 19, 2000. We were formed by Mr. John C. Francis, the principal
stockholder, and the sole executive officer and director of the Company. During
the year ended December 31, 2002, our principal executive offices were located
at 1700 W. Horizon Ridge Parkway, Suite 202, Henderson, Nevada 89012. We have
always been a developmental stage company since our inception and we have no
operating history other than organizational matters, the initial public offering
of our securities and the filing of reports with the Securities and Exchange
Commission (the "Commission"). We have no full time or part time employees and
Mr. Francis manages our affairs.

         Our initial public offering was declared effective on November 9, 2001,
and we completed our initial public offering on February 14, 2002. We sold a
total of 600,000 units in our IPO, at a price of $0.03 per unit or a total of
$18,000. Each unit sold in the IPO, as adjusted, consists of four shares of our
common stock and one-third (1/3) of one Class A Redeemable Common Stock Purchase
Warrant. Each full Class A Warrant entitles its holder to purchase four shares
of our common stock. All of the IPO units were sold for our benefit and there
were no selling stockholders in the IPO. The IPO proceeds, together with accrued
interest, also will be returned by the escrow agent to all of the IPO investors
if, on or before May 8, 2003, we do not receive written reconfirmations from a
sufficient number of IPO investors within 20 business days of the effective date
of the reconfirmation prospectus concerning our merger with InforMedix.

         We have no operating business, nor do we intend to develop our own
operating business. Our only prospect toward operations is by seeking to effect
a business combination with a corporation or other business entity which owns an
operating business and wishes to undertake a business combination for its own
corporate purposes (a "target business"), generally related to achieving
liquidity for its stockholders. Our primary activities during 2002 involved
seeking a target business and filing reports with the Commission. As such, we
are known as a "shell" company, whose sole purpose at this time is to locate a
target business and complete a business combination. We entered into a Merger
Agreement and Plan of Reorganization with InforMedix Acquisition Corp.
("Informedix") in February 2003 and are currently seeking shareholder approval
of the merger. Under the merger agreement, we have the right to acquire
InforMedix. InforMedix's sole asset is its 100% ownership interest in
InforMedix, Inc. InforMedix, Inc., was formed in 1997 and has developed and
integrated a portable, patient-interactive monitoring device, hardware, software
and network communication system to enable pharmaceutical and biotechnology
companies, medical researchers and physicians to effectively monitor and manage
patients' medication compliance and clinical response.

         Our acquisition of InforMedix is structured as a merger of InforMedix
with and into the Company. The consideration to be paid by us in acquiring
InforMedix will consist of our issuance of approximately 14,902,400 shares of
our common stock, exclusive of up to 1,080,000 shares issuable upon exercise of
warrants to be issued to the warrant holders of InforMedix, and exclusive of
11,090,000 shares which will be surrendered for cancellation by Mr. Francis as a
condition to consummating the acquisition.

         The proposed business activities described herein classify us as a
"blank check" or "blind pool" entity. Many states have enacted statutes, rules,
and regulations limiting the sale of securities of "blank check" companies in
their respective jurisdictions. We cannot assure that any market for our Common
Stock will develop even if we are able to successfully implement our business
plan and complete a business combination with viable operations.


                                       2
<PAGE>

Item 2.  Description of Property

         During the year ended December 31, 2002, we rented office space,
telephone and secretarial services from Falcon Financial Group LLC, at 1700 W.
Horizon Ridge Parkway, Suite 202, Henderson, Nevada 89012. Our sublease was on
an oral basis, and the landlord is a non-affiliated third party. Falcon is an
entity controlled by our chief executive officer. The rent charged was $50 per
month, which we will repay upon completion of a business combination, from the
proceeds of the initial public offering or by the target business.

         Upon completion of the proposed merger with InforMedix, the Company
intends to relocate its corporate officers to those of InforMedix at 5880
Hubbard Drive, Rockville, MD 20852-4821; (Tel) (301) 984-1566.

         InforMedix leases its facilities in Rockville, Maryland from a
non-affiliated landlord. The current lease commenced on March 1, 2003 for a
one-year term at $2,294 per month.

Item 3.  Legal Proceedings

         We are not a party to any pending legal proceedings.

Item 4.  Submission of Matters to a Vote of Security Holders

         No matter was submitted to a vote of stockholders in the fourth quarter
of 2002.




                                       3
<PAGE>


                                     PART II

Item 5.  Market for Company's Common Equity and Related Stockholder Matters

         Our common stock is not currently traded on any public trading market.
No assurance can be given that any market for our common stock will develop.

         The authorized capital stock of the Company consists of 48,000,000
shares, of which 40,000,000 shares have been designated common stock, $0.001 par
value, and 8,000,000 shares of preferred stock, $0.001 par value. As of March
21, 2003, there were 14,500,000 shares of common stock outstanding and held of
record by 11 stockholders. No shares of preferred stock have been issued, and
the Board has not designated the rights or preferences of any class or series of
preferred stock.

         We have not declared any dividends and do not intend to in the
foreseeable future as we have no reserves. After the merger with InforMedix,
management of InforMedix may change this policy. However, since InforMedix is
still an early stage growth company, it is unlikely that its management would
declare any dividend for a while after the business combination.

Item 6.  Management's Discussion and Analysis or Plan of Operation

Forward Looking Statements

         Statements contained in this Annual Report on Form 10-KSB include
"forward-looking statements" within the meaning of Section 27A of the Securities
Act of 1933 as amended (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which could cause the actual results of the Company (sometimes referred to as
"we", "us" or the "Company"), performance (financial or operating) or
achievements expressed or implied by such forward-looking statements not to
occur or be realized. Such forward-looking statements generally are based upon
our best estimates of future results, general business combination and
acquisition activity in the marketplace, performance or achievement, based upon
current conditions and the most recent results of operations. Forward-looking
statements may be identified by the use of forward-looking terminology such as
"may," "will," "project," "expect," "plan," "believe," "estimate," "anticipate,"
"intends," "continue", "potential," "opportunity" or similar terms, variations
of those terms or the negative of those terms or other variations of those terms
or comparable words or expressions.

Plan of Operation

         We are currently in the development stage. We have no operating
business, and all our activities since inception have been related to our
formation and completing our initial public offering in which we raised $18,000
of gross proceeds from the sale of all 600,000 units that were sold. Our ability
to continue operations is contingent upon completing a business combination. To
date, we have not incurred any material costs or expenses other than those
associated with formation of the company and our public offering. On February
14, 2002, we completed our initial public offering. Pursuant to Rule 419 under
the Securities Act, the gross proceeds from the offering of $18,000 are being
held in escrow and, as of December 31, 2002, we had cash on hand $20,182
including such escrowed funds. Funds to pay for offering expenses were loaned to
us by our chief executive officer, who, through his estate planning entity, had
loaned us a total of $24,500 as of the date of this annual report. We will use
the net proceeds of the offering, exclusive of any warrant proceeds, together
with the income and interest earned thereon, if any, to repay our indebtedness
to our chief executive officer. We do not have discretionary access to any
income on the monies in the escrow account and stockholders will not receive any
distribution of the income or have any ability to direct the use or distribution
of any such income. Thus, any such income will cause the amount in escrow to
increase. Although we are entitled to request that up to 10% of the proceeds
held in escrow be released to us to pay the costs of evaluating potential
business combinations, we do not intend to do so. No cash compensation will be
paid to any officer or director in their capacities as such until after the
consummation of a business combination. Since the role of present management
after a business combination is uncertain, we cannot determine what
remuneration, if any, will be paid to present management after such a business
combination.


                                       4
<PAGE>

         If we do not complete a business combination by May 8, 2003, which is
eighteen months from the effective date of our IPO, the escrow agent will return
the escrowed funds to the investors on a proportionate basis, with interest, if
any, in accordance with SEC Rule 419.

         We have entered into a Merger Agreement and Plan of Reorganization,
dated as of February 7, 2003, with InforMedix. Our acquisition of InforMedix
Acquisition Corp. will be structured as a merger of InforMedix Acquisition Corp.
with and into Hunapu Inc. The agreement calls for our acquisition of InforMedix
Acquisition Corp., and thereby InforMedix, for an aggregate of approximately
14,902,400 shares of our common stock and the retirement of 11,090,000 shares of
our common stock owned by our current president, John C. Francis. We intend to
change our name to InforMedix Holdings Inc. and operate InforMedix as a
wholly-owned subsidiary upon completion of the transactions contemplated by the
merger agreement.

         The closing of the transactions contemplated by the merger agreement is
conditioned upon a number of factors, including satisfactory due diligence
reviews, governmental and regulatory approvals, as necessary, our filing and
causing to become effective a post-effective amendment to our registration
statement on Form SB-2 in compliance with SEC Rule 419, stockholder approval of
the merger and merger agreement and approval of at least 80% in interest of the
IPO investors of the acquisition. The proceeds from our offering currently held
in escrow will be released to us, and the securities sold in the offering will
be released to the purchasers in the offering, if we obtain shareholder approval
of the merger and merger agreement and close the transactions contemplated by
the merger agreement, our post-effective amendment to our registration statement
is declared effective and a sufficient number of purchasers in the offering
reconfirm their investment in our company. No assurance can be given that the
due diligence reviews contemplated by the merger agreement will be completed
satisfactorily, that our post-effective amendment to our registration statement
will be declared effective by the SEC, that a sufficient number of purchasers in
the offering will reconfirm their investments in our company or that all other
conditions necessary to close the transactions contemplated by the merger
agreement will be successfully completed and that we will acquire InforMedix.

Results of Operations for Year Ended December 31, 2002

         Expenses increased by $19,216 for the twelve months ended December 31,
2002 compared to the prior year. Professional fees increased by $18,219 and
other expenses increased by $997. The Company will incur substantial expenses,
in the coming year, including expenses for professional and other consulting
services, as a result of the merger with InforMedix.

         During the twelve months ended December 31, 2002, loans from our chief
executive officer increased by $11,000 to $24,500. Cash on hand for the twelve
months ended December 31, 2002 was $20,182, including the $18,000 held in escrow
pending the closing of the merger with InforMedix. Our net less for the twelve
months ended December 31, 2002 was $29,186 and our cumulative deficit during the
development stage was $48,749 as of December 31, 2002.


                                       5
<PAGE>

Rule 419 Prescribed Acquisition Criteria and Reconfirmation

         We are a so-called "blank check" company because we are a development
stage company with no specific business plan or purpose other than effect a
business combination with an unidentified company. As mentioned previously, we
were formed to raise capital and seek business opportunities believed to hold a
potential for profit. We will primarily investigate the possible acquisition of
business interests by merger, consolidation, stock for stock exchange or
purchase of assets.

         Our initial public offering is subject to Rule 419 under the Securities
Act. As such, among other things, the fair market value of the business or
assets to be acquired must represent at least 80% of the proceeds of our public
offering, including the warrant proceeds. For purposes of our blank check
offering, the fair market value of the business or assets to be acquired must be
at least $814,400. Once an acquisition agreement meeting the above criteria has
been executed, we must successfully complete a reconfirmation offering as
described below.

Post-Effective Amendment

         Pursuant to Rule 419, once an agreement governing a business
combination meeting the above criteria had been executed, we were required to
update the registration statement with a post-effective amendment. The
post-effective amendment had to contain information about the proposed
acquisition candidate and its business, including audited financial statements,
the results of this offering, and the use of the funds disbursed from the escrow
account, if any. The post-effective amendment also had to include the terms of
the reconfirmation offer mandated by Rule 419. The reconfirmation offer requires
satisfaction of certain prescribed conditions before the offering proceeds and
shares can be released from escrow.

Reconfirmation Offering

         The reconfirmation offer must commence within five business days after
the effective date of the post-effective amendment. Under Rule 419, the
reconfirmation offer must include the following conditions:

     1.  The prospectus contained in the post-effective amendment will be sent
         to each investor whose securities are held in the escrow account within
         five business days after the effective date of the post-effective
         amendment;

     2.  Each investor will have no fewer than 20, and no more than 45 business
         days from the effective date of the post-effective amendment to notify
         us in writing that the investor elects to remain an investor;

     3.  If we do not receive written notification from any investor within 45
         business days following the effective date, the pro rata portion of the
         offering proceeds (with any interest or dividends) held in the escrow
         account on such investor's behalf will be returned to the investor
         within five business days by first class mail or other equally prompt
         means;

                                       6
<PAGE>

     4.  The business combination will be consummated only if a sufficient
         number of investors elect to reconfirm their investments;

     5.  If a consummated business combination has not occurred within 18 months
         from November 9, 2001 (the date of the commencement of our offering) or
         May 8, 2003, the offering proceeds held in the escrow account shall be
         returned to all investors on a pro rata basis within five business days
         by first class mail or other equally prompt means;

     6.  Investors who receive their pro rata portion of the offering proceeds
         will also receive the interest, if any. If we consummate a business
         combination, investors who have elected to remain investors will not
         receive any interest when their pro rata portion of the offering
         proceeds is released to us.


Release of Offering Proceeds and Shares from Escrow

         The offering proceeds and shares held in escrow may be released to us
and the investors, respectively, after the escrow agent has received a signed
representation from us and any other evidence acceptable to the escrow agent
that:

     1.  We have executed an agreement for the combination with a business for
         which the fair value of the business represents at least 80% of the
         offering proceeds and have filed the required post-effective amendment;

     2.  The post-effective amendment has been declared effective, the mandated
         reconfirmation offer prescribed by Rule 419 has been completed and we
         have satisfied all of the prescribed conditions of the reconfirmation
         offer;

     3.  The combination with a business with a fair value of at least 80% of
         the offering proceeds, including the warrant proceeds, has been
         consummated.

Employees

         We are a development stage company and currently have no employees,
other than our chief executive officer, John C. Francis, who serves without
compensation. Mr. Francis has devoted only a small portion of his time (less
than 10%) to our affairs on a part-time or as-needed basis increasing in time
when a target business is identified. We have used outside consultants,
advisors, attorneys and accountants as necessary, none of which were hired on a
retainer basis. We do not anticipate hiring any full-time employees pending the
closing of the transaction with InforMedix. InforMedix currently has six
employees and five part time consultants.





                                       7
<PAGE>

                                  RISK FACTORS


         Our securities are highly speculative and subject to numerous and
substantial risks, including, but not limited to, these discussed below.

Risks Relating to Our Financial Condition Following the Acquisition

         If InforMedix does not obtain additional financing, it may be forced
         out of business and you could thereby lose your entire investment.

         InforMedix will require additional financing in order to fully
         implement its business plan. Such additional financing may be in the
         form of debt or equity financing by InforMedix. We can give no
         assurance that InforMedix will be able to obtain such financing, that
         such financing will be available on terms beneficial to us, InforMedix
         or our stockholders, that the funds so obtained will be sufficient to
         fully implement InforMedix's business plan, or that a full
         implementation of such business plan will result in our profitability.
         We intend to pursue various possible financing options to raise such
         additional financing. These options include one or more public
         offerings or private placements of debt or equity securities. If we are
         unable to obtain additional financing following our acquisition of
         InforMedix, we may have to curtail or suspend InforMedix's operations,
         and you could lose your entire investment in our company.

         If InforMedix continues to incur negative cash flow from its
         operations, you could lose your entire investment in our company.

         InforMedix has not generated net positive cash flow from its operations
         since its inception in 1997. InforMedix had a net loss of $2,265,677 on
         net sales of $22,759 for the year ended December 31, 2002, and loss of
         $1,804,672 on net sales of $44,221 for the year ended December 31,
         2001, and a cumulative loss from inception through December 31, 2002 of
         $12,010,471.

         InforMedix has funded its operating activities primarily through sales
         of equity securities to its founders, individual accredited investors,
         corporate investors, private investment lenders and equity issued for
         services in the amount of approximately $11,107,930 as of December 31,
         2002. In addition, the Company borrowed $695,000 from its Chief
         Executive Officer, directors and private investors as of December 31,
         2002 and an additional $65,000 in 2003. InforMedix anticipates negative
         cash flow from operations to continue for the foreseeable future. We do
         not anticipate that this form of shareholder and executive officer
         funding will continue after we acquire InforMedix. Accordingly, we can
         give no assurance that InforMedix will be able to operate profitably or
         be able to produce positive cash flow from operations in the future.
         InforMedix's efforts to operate profitably and obtain positive cash
         flow from operations will depend on, among other things:

         o        developing the InforMedix brand, marketing and other
                  promotional activities of the Med-e Monitor system;

         o        expanding its product offerings, including the number of
                  products available for sale;

         o        developing marketing and distribution relationships with
                  strategic business partners;

         o        expanding general and administrative functions to support any
                  growth that may occur; and

                                       8
<PAGE>

         o        establishing and developing relationships in the healthcare
                  industry, particularly with pharmaceutical manufacturers,
                  contract research organization (C.R.O.'s), academic research
                  centers, and disease management companies.

         Qualified financial statements based on operating losses and a capital
         deficit question InforMedix's ability to continue in business.

         InforMedix incurred substantial net losses and negative cash flow from
         operations in 2001 and 2002. InforMedix's accountants issued a
         qualified report on its financial statements for the year ended
         December 31, 2002. The report states that InforMedix is currently in
         the development stage and there is no guarantee whether the Company
         will be able to generate enough revenue and/or raise capital to support
         current operations and expand sales. This raises substantial doubt
         about InforMedix's ability to continue as a going concern.

Risks Relating to the Proposed Acquisition

         If we do not complete the acquisition of InforMedix, we and our
         stockholders will face uncertainty over the future of our company.

         The proposed acquisition transaction is subject to a number of
         conditions, including, but not limited to, the reconfirmation of their
         respective purchases by investors who purchased, at a minimum, an
         aggregate of 480,000 units in our IPO, shareholder approval of the
         merger and the merger agreement, satisfactory due diligence review, no
         material adverse change in InforMedix's business, and any government
         and regulatory approvals. We are required by SEC Rule 419 to promptly
         return to the IPO investors the funds that they paid for their units in
         the IPO which are being held in escrow if we do not complete the
         proposed transaction and, on or before May 8, 2003, we do not receive a
         sufficient number of the IPO investors' reconfirmations of their
         respective purchases following delivery to them of another
         reconfirmation prospectus containing required information and
         disclosures concerning another proposed business transaction. In this
         event, the IPO investors would achieve no return on their initial
         purchases in the IPO other than the interest earned on their investment
         funds while such funds were held in escrow.

         If we fail to establish the Med-e Monitor System brand or to attract
         repeat customers, InforMedix may not be able to increase its revenues
         sufficiently to fund its operations.

         Following our acquisition of InforMedix, we must develop, establish and
         strengthen the InforMedix brand for the Med-e Monitor System,
         particularly because of the early stage of InforMedix's development and
         the highly competitive nature of its business. If we fail to establish
         the Med-e Monitor System brand quickly, InforMedix will be at a
         competitive disadvantage and may lose the opportunity to obtain, and
         thereafter maintain, a sufficient number of customers. The development
         of the Med-e Monitor System brand will depend largely on the success of
         InforMedix's marketing efforts and its ability to provide consistent,
         high quality customer experiences. We cannot be certain that the Med-e
         Monitor System brand promotion activities will be successful, or will
         result in increased revenues. If we achieve increased InforMedix
         revenues, there can be no assurance that these revenues will be
         sufficient to offset the expenditures incurred in building the Med-e
         Monitor System brand.

                                       9
<PAGE>

         InforMedix is obligated to comply with extensive government regulation
         and its failure to do so could result in significant liability.

         The technology used in the monitoring of clinical drug trial protocols
         is regulated by the Food and Drug Administration. Although InforMedix
         believes that its Med-eMonitor System will be in compliance with these
         regulations when fully commercially implemented, we can give no
         assurance:

         o        that the process to comply with such regulations will not
                  require significant effort and expense, or

         o        that InforMedix will have sufficient funds to document the
                  regulatory compliance of its Med-eMonitor System.

         If InforMedix fails to document regulatory compliance, because of a
         lack of funds, or otherwise, we may be required to curtail or suspend
         InforMedix's operations.

         We will lack business diversification.

         As a result of our limited resources, we expect to have limited
         proceeds to expand our business beyond that currently conducted by
         InforMedix. Accordingly, the prospects for our success initially will
         be entirely dependent upon the future performance of a single product
         and a single business. Unlike certain entities that have the resources
         to consummate several business combinations or entities operating in
         multiple industries or multiple segments of a single industry, we will
         not have the resources to diversify our operations or benefit from the
         possible spreading of risks or offsetting of losses.

         We have a limited ability to evaluate management of a target business.

         We expect our present management to play no managerial role in the
         company following a business combination, including our proposed
         acquisition of InforMedix. Although we have negotiated with the
         management of InforMedix in connection with our evaluation of a
         business combination with such company, our assessment of management
         may be incorrect.

         In evaluating a prospective target business, we have considered several
         factors, including the following:

         o        experience and skill of management and availability of
                  additional personnel of the target business;

         o        costs associated with effecting the business combination;

         o        equity interest retained by our stockholders in the merged
                  entity;

         o        growth potential of the target business;

         o        capital requirements of the target business;

         o        capital available to the target business;

         o        competitive position of the target business;

         o        stage of development of the target business;

         o        degree of current or potential market acceptance of the target
                  business, products or services;

         o        proprietary features and degree of intellectual property or
                  other protection of the target business;

         o        the financial statements of the target business; and

                                       10
<PAGE>

         o        the regulatory environment in which the target business
                  operates.

         There may be adverse tax consequences as a result of the merger.

         As a general rule, Federal and state tax laws and regulations have a
         significant impact upon the structuring of business combinations. We
         have evaluated the possible tax consequences of any prospective
         business combination and endeavored to structure the acquisition
         transaction so as to achieve the most favorable tax treatment to our
         company, the target business and our stockholders. There can be no
         assurance that the Internal Revenue Service or relevant state tax
         authorities will ultimately assent to our tax treatment of a particular
         consummated business combination. To the extent the IRS or any relevant
         state tax authorities ultimately prevail in recharacterizing the tax
         treatment of a business combination, there may be adverse tax
         consequences to our company, the target business, and our stockholders.

         Both InforMedix and our company were recently organized and have no or
         limited operating history upon which you can base an investment
         decision.

         We were organized on January 19, 2000 and, through December 31, 2002,
         our efforts were limited primarily to organizational activities,
         preparing our registration statement and identifying and negotiating
         potential acquisition partners. We do not have any operating history or
         experience upon which you can make an investment decision. InforMedix
         was incorporated on January 27, 1997 and has a limited operating
         history upon which you can make an investment decision, or upon which
         we can accurately forecast future sales. You should, therefore,
         consider us subject to all of the business risks associated with a new
         business. The likelihood of our success must be considered in light of
         the expenses, difficulties and delays frequently encountered in
         connection with the formation and initial operations of a new and
         unproven business.

         There was no independent valuation of InforMedix upon which you can
         base an investment decision.

         The number of shares of our common stock to be issued pursuant to the
         merger agreement was determined by negotiation between InforMedix and
         us. This consideration does not necessarily bear any relationship to
         InforMedix's asset value, net worth or other established criteria of
         value and should not be considered indicative of the actual value of
         InforMedix or us. Furthermore, neither InforMedix nor us has obtained
         either an appraisal of any entity or their respective securities or an
         opinion that the merger is fair from a financial perspective.

Risks Involving Our Securities

         If we redeem the warrants, the value of your investment may be reduced.

         We may redeem our Class A Warrants at a price of $.001 per warrant at
         any time during the warrant exercise period. If you do not exercise
         your warrants prior to their expiration or redemption, you will not be
         able to purchase the shares of common stock underlying your warrants.
         If we call for redemption of any of the warrants, you will have to (a)
         exercise the warrants (and pay the exercise price at a time when it may
         be disadvantageous for you to do so), (b) sell the warrants at the
         current market price when you might otherwise wish to hold the warrants
         for possible additional appreciation, or (c) accept the redemption
         price, which may be substantially less than the market value of the
         warrants at the time of redemption.

                                       11
<PAGE>

         If we do not keep a registration statement current, you will not be
         able to exercise your warrants.

         We must keep a registration statement effective with the SEC in order
         for you to exercise your warrants. We may not be able to maintain a
         registration statement in effect throughout the period during which the
         warrants remain exercisable. Maintaining an effective registration
         statement requires substantial continuing expenses for legal and
         accounting fees and we cannot guarantee our ability to keep the
         registration statement effective. We will instruct our warrant agent to
         suspend the exercise of warrants if this or any future registration
         statement with respect to the shares underlying the warrants is no
         longer effective.

         If we do not qualify our securities in states other than New York, your
         resale of any securities you acquire under a reconfirmation prospectus
         may be limited and you may not be able to exercise your warrants.

         We offered and sold the IPO units only in the State of New York. We
         believe that the common stock and warrants comprising the units will be
         eligible for sale on a secondary market basis in other states based
         upon applicable exemptions from that state's registration requirements,
         subject, in each case, to the exercise of the broad discretion and
         powers of the securities commission or other administrative bodies
         having jurisdiction in each state and any changes in statutes and
         regulations which may occur after the date of this prospectus. However,
         the lack of registration in most states and the requirement of a seller
         to comply with the requirements of state blue sky laws in order for the
         seller to qualify for an applicable secondary market sale exemption,
         may cause an adverse effect on the resale price of our securities, as
         well as the delay or inability of a holder of our securities to dispose
         of such securities.

         In addition, the warrants and underlying securities will be exercisable
         only in New York. We may decide not to seek, or may not be able to
         obtain, registration for the issuance of the underlying securities in
         the state where you live during the period when the warrants are
         exercisable. We cannot issue securities to you upon exercise of your
         warrants unless either (a) the securities issuable upon exercise of the
         warrants are registered in your state or (b) an exemption from
         registration is available. We may not be able to qualify the warrants,
         in which case the warrants would become unexercisable and deprived of
         value.

         Common Stock Immediately Eligible for Resale

         Of the 14,500,000 shares of common stock outstanding of the Company as
         of the date of this Annual Report, all are currently held in escrow
         pending completion of a business combination promulgated under the
         Securities Act. Under Rule 144 ("Rule 144"), as currently in effect,
         subject to the satisfaction of certain other conditions, a person,
         including an affiliate of the Company (or persons whose shares are
         aggregated), who has owned restricted shares of common stock
         beneficially for at least one year is entitled to sell, within any
         three-month period, a number of shares that does not exceed the greater
         of 1% of the total number of outstanding shares of the same class or,
         if the common stock is quoted on an exchange or NASDAQ, the average
         weekly trading volume during the four calendar weeks preceding the
         sale. A person who has not been an affiliate of the Company for at
         least three months immediately preceding the sale and who has
         beneficially owned the shares of common stock to be sold for at least
         two years is entitled to sell such shares under Rule 144 without regard
         to any of the limitations described above. No prediction can be made as
         to the effect, if any, that sales of such shares of common stock or the
         availability of such shares for sale will have on the market prices, if
         any, for shares of common stock prevailing from time to time.
         Nevertheless, the sale of substantial amounts of common stock in the
         public market would likely adversely affect prevailing market prices
         for the common stock and could impair our ability to raise capital
         through the sale of equity securities.

                                       12
<PAGE>

         We Are Authorized to Issue Preferred Stock

         Our Certificate of Incorporation authorizes the designation and
         issuance of 8,000,000 shares of preferred stock (the "preferred
         stock"). As part of the InforMedix merger we intend to seek shareholder
         approval to amend our certificate to create blank check preferred stock
         with such designations, powers, preferences, rights, qualifications,
         limitations and restrictions of such series as the Board, subject to
         the laws of the State of Nevada, may determine from time to time.
         Accordingly, the Board would be empowered, without stockholder
         approval, to designate and issue preferred stock with dividend,
         liquidation, conversion, voting or other rights which could adversely
         affect the voting power or other rights of the holders of common stock.
         In addition, the preferred stock could be utilized, under certain
         circumstances, as a method of discouraging, delaying or preventing a
         change our control. Although we do not currently intend to designate or
         issue any shares of preferred stock, there can be no assurance that we
         will not do so in the future. It is likely however, that following a
         business combination, new management may issue such preferred stock,
         and it is possible that one or more series of preferred stock will be
         designated and/or issued in order to effectuate a business combination
         or financing. As of this date, we have no outstanding shares of
         preferred stock.

         We have not paid and do not intend to pay dividends.

         We have not paid any dividends on our common stock to date and do not
         intend to pay dividends prior to our combination with a target
         business. The payment of dividends after any such business combination,
         if any, will be entirely within the discretion of our board of
         directors. Accordingly, you will have to look to appreciation in the
         value of your securities to obtain a return on your investment.

Item 7.  Financial Statements

         See the Consolidated Financial Statements and related Report of
Independent Certified Public Accountants included herewith as pages F-1 through
F-8.

Item 8.  Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure

         None.



                                       13
<PAGE>


                                    PART III

Item 9.  Directors, Executive Officers, Promoters and Control Persons;
Compliance With Section 16(a) of the Exchange Act.

         (a) The following table provides information concerning the sole
executive officer and director of the company. All directors hold office until
the next annual meeting of stockholders or until their successors have been
elected and qualified.

Name                         Age                Title
----                         ---                -----
John C. Francis              53                 Chief Executive Officer,
                                                President, and Director

         John C. Francis has served as our President, Chief Executive Officer
and director since Hunapu's formation in January 2000. He has served as Vice
President, Chief Financial Officer and a director of Crest View Inc., a company
formed to develop and operate an "eco-resort" and cultural center on Guanaja,
Honduras and to develop and market a line of medicinal herbs and natural healing
products, since July 2001. Mr. Francis has served as President and Chief
Executive Officer of Acalan, LLC since its formation in 1998. Acalan is a new
media company specializing in the development, production and distribution of
transformational media. Transformational media is material intended to transform
the spirit, as well as inform the mind. Mr. Francis also has been a managing
member of Falcon Financial Group LLC since January 2000. He served as Chief
Financial Officer (from April 1994 to April 1996), Vice President, Secretary and
a director (April 1994 through January 1999) of AgriBioTech, Inc. AgriBioTech
and several of its subsidiaries filed a voluntary petition for bankruptcy in
January 2000, approximately eleven months following Mr. Francis' departure from
the company and its assets were sold by the bankruptcy court. Mr. Francis
devotes less than 10% of his business hours to our affairs.

         (b) The Company is not subject to Section 16(a) of the Exchange Act.


Meetings of the Board

         Our sole director is, and always has been, Mr. Francis. As of March 21,
2003, the Board of Directors, by written consent signed by the sole director, in
lieu of a meeting, approved and ratified all actions taken by management
including all agreements and stock issuances in fiscal 2002. As we only have one
board member, we do not have separate or independent audit or compensation
committees.

Item 10.  Executive Compensation

         Since our inception, we have paid no cash compensation to our officers
or directors. John C. Francis is the sole officer and director of the Company.
Mr. Francis receives no compensation for his services as the sole director
and/or executive officer of the Company. Mr. Francis has loaned the Company the
funds for the reasonable business expenses of the Company, including those
incurred in connection with the formation of the Company, the preparation and
filing of a Registration Statement on Form SB-2 under the Securities Act and the
completion of the initial public offering. Mr. Francis and his affiliate will
also be entitled to be reimbursed for any future reasonable business expenses of
the Company, including any expenses incurred in connection with any business
combination. This will include reimbursement for the cost of the personnel of
Mr. Francis or his affiliates (other than Mr. Francis himself) to be inclusive
of all documented costs of their employment on a reasonable hourly or daily
allocation while engaged in activities on behalf of the Company.

                                       14
<PAGE>

         While the Company does not presently anticipate engaging the services
of professional firms that specialize in finding business acquisitions on any
formal basis, the Company may engage such firms in the future, in which event
the Company may pay a finder's fee or other compensation. In no event, however,
will the Company pay a finder's fee or commission to any officer and director of
the Company or any entity with which he is affiliated for such service.
Moreover, in no event shall the Company issue any of its securities to any
officer, director or promoter of the Company, or any of their respective
affiliates or associates, in connection with activities designed to locate a
target business. The Company does not have any incentive or stock option plan in
effect.

                                       15
<PAGE>

Item 11.  Security Ownership of Certain Beneficial Owners and Management

         The following table sets forth certain information regarding the number
and percentage of common stock (being our only voting securities) beneficially
owned by each officer and director, each person (including any "group" as that
term is used in Section 13(d)(3) of the Securities Exchange Act of 1934) known
by us to own 5% or more of our common stock, and all officers and directors as a
group, as of the date of this report.

                                Amount and
                                 Nature of               Percentage of
                                 Beneficial                Outstanding
Name                            Ownership (1)           Shares Owned (2)
----                            -------------           ----------------
John C. Francis (3)             12,826,667(4)                 82.8%
P.O. Box 50464
Henderson, Nevada 89016

Hughes Holdings LLC             2,522,667 (5)                16.67%
125 Michael Drive
Syosset, NY 11791

All Officers and                 12,826,667                   82.8%
Directors as a Group
(one person)

--------------------
(1)      Unless otherwise indicated, the company has been advised that all
         individuals listed have the sole power to vote and dispose of the
         number of shares set forth opposite their names. For purposes of
         computing the number and percentage of shares beneficially owned by a
         selling securityholder, any shares which such person has the right to
         acquire within 60 days are deemed to be outstanding, but those shares
         are not deemed to be outstanding for the purpose of computing the
         percentage ownership of any other selling securityholder.

(2)      Based on 14,500,000 shares issued and outstanding without giving effect
         to the potential issuance of additional common stock upon the exercise
         of the class A warrants.

(3)      Mr. Francis is chief executive officer, president, treasurer and sole
         director of the company.

(4)      Consists of 11,840,000 shares of common stock and 986,667 class A
         warrants registered in the name of Putun LLC, an entity established by
         Mr. Francis for estate planning purposes.

(5)      Represents 1,892,000 shares of common stock and 630,667 shares of our
         common stock issuable upon exercise of class A warrants. Of this
         amount, Hughes Holdings LLC has notified Hunapu that it intends to
         transfer a total of 1,376,000 shares of common stock and Class A
         Warrants to purchase 458,667 shares of common stock for cash, services,
         and/or gifts to approximately 10 different persons upon the completion
         of the proposed merger with InforMedix. The beneficial owners of Hughes
         Holdings LLC are Robert DePalo, Cori Orr and Gary Schonwald. Mr. DePalo
         is the Chief Executive Officer of Rockwell Capital Partners,
         InforMedix's investment banker and Director of Corporate Finance of
         Vertical Capital Partners, the NASD broker-dealer placement agent for
         InforMedix.



                                       16
<PAGE>


Item 12.  Certain Relationships and Related Transactions

         On January 19, 2000, upon the formation of the company, John C.
Francis, founder and Chief Executive Officer, purchased through Putun LLC, an
entity established by Mr. Francis for estate planning purposes, 2,960,000 shares
of common stock from the company for an aggregate of $2,960, or $.001 per share.
Mr. Francis tendered a recourse promissory note for his shares which was paid in
May 2000 when we opened a bank account.

         During the year ended December 31, 2002, we rented office space,
telephone and secretarial services, at 1700 West Horizon Ridge Parkway - Suite
202, Henderson, Nevada, from Falcon Financial Group LCC. This location served as
our principal place of business. Our sublease with Falcon was oral. The landlord
for the property was a non-affiliated third party. Falcon is an entity
controlled by John C. Francis, our chief executive officer, and a business
associate of Mr. Francis. We paid Falcon $50 per month for the renting of this
office and being provided telephone and secretarial services. We anticipate that
we will relocate our principal place of business to InforMedix's offices at 5880
Hubbard Drive, Rockville, Maryland 20852-4821.

Set forth below are the dates on which we borrowed funds from Putun LLC, the
estate planning entity established by Mr. Francis and of which he is its
manager, the amounts of such loans and their original due dates.

                                    Original
Borrowing Date                       Amount                     Due Date
--------------                       ------                     --------
August 31, 2000                     $   7,500                August 30, 2002
February 12, 2001                       2,000               February 11, 2002
April 6, 2001                           4,000                 April 5, 2002
April 19, 2002                          3,000                April 18, 2003
November 21, 2002                       8,000               November 21, 2003
February 25, 2003                       2,500                 May 25, 2003

Each of these loans bears interest at 6% per annum. In addition, Putun has
extended the due date of each of the first four loans to the earlier of June 9,
2003 or our completion of a business acquisition such as those contemplated by
the InforMedix merger agreement. As of December 31, 2002, we had not repaid any
of these loans and had accrued $1,943 in interest charges due in connection with
these loans. These notes shall be repaid from the release of the IPO proceeds
from escrow upon the completion of the merger.


                                       17
<PAGE>

Conflicts of Interest

         In order to minimize potential conflicts of interest relating to non
arms-length transactions, (i) we will not combine with any target business in
which our officers, directors or non-public stockholders, or their respective
affiliates, serve as officers, directors or partners or own or hold an ownership
interest, (ii) none of such persons shall receive from us or the target business
or its principals any finder's fees, consulting fees or similar compensation,
whether in cash, securities or otherwise, for introducing to us a target
business, and (iii) our management will not negotiate or otherwise consent to
the purchase of their respective common stock as a condition of or in connection
with our proposed combination with a target business. There is no cap on the
amount of finder's fees that we may pay.




                                       18
<PAGE>

Item 13.  Exhibit List and Reports on Form 8-K.

(a)      Exhibits

  Exhibit
  Number    Description
    3.1    Articles of Incorporation. (1)
    3.2    By-Laws. (1)
    4.1    Specimen common stock certificate. (1)
    4.2    Specimen Class A Warrant certificate. (1)
   10.1    Escrow Agreement, between Hunapu Inc. and Southwest
           Escrow Company.(2)
   10.2    Promissory Notes, made August 31, 2000. (3)
   10.3    Promissory note, made February 12, 2001. (3)
   10.4    Promissory note, made April 6, 2001. (3)
   10.5    Letter from Putun, LLC, dated August 30, 2001, extending due date
           of Promissory Note made August 31, 2000. (4)
   10.6    Agreement of Putun, LLC agreeing to extend due dates of Promissory
           Notes. (4)
   10.7    Merger Agreement and Plan of Reorganization, dated as of
           February 7, 2003, between Hunapu Inc. and InforMedix
           Acquisition Corp. (5)
   10.8    Hunapu Inc. 2003 Stock Incentive Plan (5)
   10.9    Promissory note made November 21, 2002. (5)
   10.10   Promissory note made February 25, 2003.(5)
   99.1    Certification pursuant to 18 U.S.C. Section 1350

--------------
   (1)     Incorporated by reference from the Company's Registration
           Statement on Form SB-2 filed with the Commission on September 9,
           2000.
   (2)     Incorporated by reference from Amendment No. 1 to the Company's
           Registration Statement on Form SB-2 filed with the Commission on
           December 28, 2000.
   (3)     Incorporated by reference from Amendment No. 3 to the Company's
           Registration Statement on Form SB-2 filed with the Commission
           on July 6, 2001.
   (4)     Incorporated by reference from Amendment No. 4 to the Company's
           Registration Statement on Form SB-2 filed with the Commission on
           October 16, 2001.
   (5)     Incorporated by reference from the Company's Post-Effective
           Amendment No. 4 to its Registration Statement on Form SB-2 filed with
           the Commission on March 25, 2003

(b)  Reports on Form 8-K

         No reports on Form 8-K were filed during the fourth quarter of 2002.

Item 14.  Controls and Procedures

         An evaluation was performed as of March 21, 2003, under the supervision
of John Francis, our sole officer and director, of the effectiveness of the
design and operation of our disclosure controls and procedures. Based on such
evaluation, Mr. Francis has concluded that our disclosure controls and
procedures were effective as of March 21, 2003. There have been no significant
changes in our internal controls or in other factors that could significantly
affect our internal controls subsequent to March 21, 2003.


                                       19

<PAGE>

                          INDEPENDENT AUDITORS' REPORT


To the Shareholders
Hunapu Inc.
Henderson, Nevada


We have audited the accompanying balance sheets of Hunapu Inc. (a development
stage company), as of December 31, 2002 and 2001, and the related statements of
operations, shareholders' equity and cash flows for the cumulative period from
January 19, 2000 to December 31, 2002 (the development stage) and the years
ended December 31, 2002 and 2001. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above, present fairly, in
all material respects, the financial position of Hunapu Inc. (a development
stage company) as of December 31, 2002 and 2001, and the results of its
operations and its cash flows for the years then ended and the cumulative period
from January 19, 2000 to December 31, 2002 (the development stage), in
conformity with accounting principles generally accepted in the United States of
America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 1 to the
financial statements, the Company has been in the development stage since its
inception on January 19, 2000. The Company's lack of financial resources and
liquidity raise substantial doubt about its ability to continue as a going
concern. Management's plans in regard to this matter are also described in Note
1. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.



                                         /s/ Lazar Levine & Felix LLP
                                         --------------------------------
                                         LAZAR LEVINE & FELIX LLP

New York, New York
March 14, 2003



                                      F - 1

<PAGE>

                                   HUNAPU INC.
                          (A Development Stage Company)
                                 BALANCE SHEETS


<TABLE>
<CAPTION>

                                                                                                    December 31,
                                                                                    -----------------------------------------
                                                                                             2002                   2001
                                                                                    -----------------       -----------------
<S>                                                                                 <C>                     <C>
                                   - ASSETS -

CURRENT ASSETS:
     Cash                                                                           $           2,182       $           2,572
                                                                                    -----------------       -----------------
                                                                                                2,182                   2,572
OTHER ASSETS:
     Cash held in escrow                                                                       18,000                      -
                                                                                    -----------------       ----------------


TOTAL ASSETS                                                                        $          20,182       $           2,572
                                                                                    =================       =================



               - LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) -

CURRENT LIABILITIES:
     Accrued expenses                                                               $          27,031       $           5,635
     Loan payable - shareholder                                                                24,500                  13,500
                                                                                    -----------------       -----------------
TOTAL CURRENT LIABILITIES                                                                      51,531                  19,135
                                                                                    -----------------       -----------------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY (DEFICIT):
     Preferred stock, $.001 par value; 8,000,000 shares authorized, none issued                    -                       -
     Common stock, $.001 par value;  40,000,000 shares authorized,  14,500,000 and
       3,000,000 shares issued and outstanding at 2002 and 2001, respectively                  14,500                   3,000
     Additional paid-in capital                                                                 2,900                      -
     Deficit accumulated during the development stage                                         (48,749)                (19,563)
                                                                                    ------------------      ------------------
                                                                                              (31,349)                (16,563)
                                                                                    ------------------      ------------------

                                                                                    $          20,182       $           2,572
                                                                                    =================       =================
</TABLE>


                             See accompanying notes


                                     F - 2
<PAGE>



                                   HUNAPU INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS


<TABLE>
<CAPTION>
                                       Cumulative During the
                                            Development
                                              Stage                           For The Year Ended December 31,
                                         (January 19, 2000 to            -----------------------------------------
                                         December 31, 2002)                  2002                         2001
                                         ------------------                  ----                         ----

<S>                                      <C>                             <C>                           <C>
REVENUES                                     $      --                   $      --                     $      --
                                             -----------                 -----------                   -----------

COSTS AND EXPENSES:
     Filing fees                                   5,830                       3,685                           355
     Professional fees                            35,219                      23,719                         5,500
     Other expenses                                5,757                         724                         3,380
     Interest expense                              1,943                       1,058                           735
                                             -----------                 -----------                   -----------
                                                  48,749                      29,186                         9,970
                                             -----------                 -----------                   -----------

NET LOSS                                        $(48,749)                   $(29,186)                     $ (9,970)
                                             ===========                 ===========                   ===========

LOSS PER SHARE BASIC AND DILUTED                       0                           0                             0
                                             ===========                 ===========                   ===========

WEIGHTED AVERAGE
   NUMBER OF COMMON SHARES
   OUTSTANDING                                12,737,546                  14,174,247                    12,000,000
                                             ===========                 ===========                   ===========

</TABLE>

                                      F - 3

<PAGE>



                                   HUNAPU INC.
                          (A Development Stage Company)
                   STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT)

<TABLE>
<CAPTION>
                                                                                                   Deficit
                                                                                                 Accumulated
                                                      Common Shares                                 During the        Shareholders'
                                                 -----------------------       Additional        Development             Equity
                                                 Number           Amount     Paid-In Capital         Stage              (Deficit)
                                                 ------           ------     ---------------         -----              ---------
<S>                                            <C>           <C>              <C>                 <C>               <C>
At inception, January 19, 2000                         -     $          -     $          -        $         -       $          -

Issuance of common units                        3,000,000           3,000                -                  -              3,000

Net loss for the period ended December
   31, 2000                                            -                -                -              (9,593)            (9,593)
                                               ----------    -------------    -------------       ------------      --------------

Balance at December 31, 2000                    3,000,000            3,000               -              (9,593)            (6,593)

Net loss for the year ended December 31,
   2001                                                -                -                -              (9,970)            (9,970)
                                               ----------    -------------    -------------       ------------      --------------

Balance at December 31, 2001                    3,000,000            3,000               -             (19,563)           (16,563)

Issuance of compensatory shares                   100,000              100            2,900                 -               3,000

Common units sold in initial public
   offering                                       600,000              600           17,400                 -              18,000

Expenses incurred re: initial public
   offering                                            -                -            (6,600)                -              (6,600)

300% stock dividend                            10,800,000           10,800          (10,800)                -                   -

Net loss for the year ended December 31,
   2002                                                -                -                -             (29,186)           (29,186)
                                               ----------    -------------    -------------       ------------      --------------

Balance at December 31, 2002                   14,500,000    $      14,500    $       2,900       $    (48,749)     $     (31,349)
                                               ==========    =============    =============       =============     ==============

</TABLE>


                             See accompanying notes

                                     F - 4
<PAGE>




                                   HUNAPU INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>

                                                           Cumulative During the
                                                             Development Stage
                                                            (January 19, 2000 to        For The Year Ended December 31,
                                                             December 31, 2002)          2002                  2001
                                                           ----------------------    ---------------     -----------------
<S>                                                        <C>                       <C>                 <C>
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:

CASH FLOWS FROM OPERATING ACTIVITIES:
     Net loss                                                    $(48,749)                $(29,186)           $ (9,970)
     Compensatory shares                                            3,000                    3,000                   -
     Adjustment to reconcile net loss to net cash
      utilized by operating activities
       Increase in accrued expenses                                27,031                   21,396               5,485
                                                                 --------                 --------            --------
        Net cash utilized by operating activities                 (18,718)                  (4,790)             (4,485)
                                                                 --------                 --------            --------


CASH FLOWS FROM FINANCING ACTIVITIES:
     Proceeds from officers' loans                                 24,500                   11,000               6,000
     Sale of common units                                          21,000                   18,000                   -
     Expenses paid re sale of common units                         (6,600)                  (6,600)                  -
                                                                 --------                 --------            --------

        Net cash provided by financing activities                  38,900                   22,400               6,000
                                                                 --------                 --------            --------

NET INCREASE IN CASH AND CASH EQUIVALENTS                          20,182                   17,610               1,515

     Cash and cash equivalents at beginning of period                   -                    2,572               1,057
                                                                 --------                 --------            --------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                       $ 20,182                 $ 20,182            $  2,572
                                                                 ========                 ========            ========

</TABLE>
                             See accompanying notes

                                     F - 5

<PAGE>



                                   HUNAPU INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                           DECEMBER 31, 2002 AND 2001

NOTE 1 - DESCRIPTION OF COMPANY:

         Hunapu Inc., ("the Company"), was organized in the state of Nevada on
         January 19, 2000. The Company was formed to serve as a vehicle to raise
         capital to acquire a business and is currently considered a "blank
         check" company inasmuch as the Company is not generating revenues and
         does not own an operating business and has no specific business plan
         other than to engage in a merger or acquisition. The Company has no
         employees and no material assets. Administrative services are currently
         being provided by an entity controlled by an officer of the Company at
         no charge. The Company's efforts to date have been limited to
         organizational activities and to seeking an appropriate merger or
         acquisition vehicle.

         The Company is considered as being in the development stage, since its
         inception, in accordance with Statement of Financial Accounting
         Standards No. 7, and its year-end is December 31.

         As shown in the financial statements, the Company has incurred net
         losses, has negative working capital and has an accumulated deficit of
         $48,749 as of December 31, 2002. It is management's assertion that
         these circumstances may hinder the Company's ability to continue as a
         going concern. The Company has completed an initial public offering of
         its securities (see Note 4 for additional information) and is currently
         seeking potential business opportunities.

         In February 2003, the Company entered into a Merger Agreement and Plan
         of Reorganization with InforMedix Acquisition Corp. Under the merger
         agreement, InforMedix is to merge with and into the Company, subject to
         specified conditions and terms set forth in the agreement. InforMedix
         Acquisition Corp.'s sole material asset is its 100% ownership interest
         in InforMedix, Inc. The consideration to be paid by the Company in
         acquiring InforMedix is as follows:

         (i)      the issuance of 14,677,400 shares of Company common stock to
                  the stockholders of InforMedix Acquisition Corp. in exchange
                  for their shares of InforMedix common stock;

         (ii)     the issuance of 225,000 shares of Company common stock to the
                  three holders of currently outstanding convertible notes of
                  InforMedix in connection with the automatic conversion of such
                  notes exclusive of accrued interest on such notes; and

         (iii)    the issuance of warrants to purchase up to a maximum of
                  1,080,000 shares of Company common stock to the holders of
                  currently outstanding warrants to purchase InforMedix common
                  stock.


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

         The Company's accounting policies are in accordance with accounting
         principles generally accepted in the United States of America. Outlined
         below are those policies considered particularly significant.


                                     F - 6

<PAGE>


                                   HUNAPU INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                           DECEMBER 31, 2002 AND 2001


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

         (a)      Use of Estimates: In preparing financial statements in
                  accordance with accounting principles generally accepted in
                  the United States of America, management makes certain
                  estimates and assumptions, where applicable, that affect the
                  reported amounts of assets and liabilities and disclosures of
                  contingent assets and liabilities at the date of the financial
                  statements, as well as the reported amounts of revenues and
                  expenses during the reporting period. While actual results
                  could differ from those estimates, management does not expect
                  such variances, if any, to have a material effect on the
                  financial statements.

         (b)      Statements of Cash Flows: For purposes of the statements of
                  cash flows the Company considers all highly liquid investments
                  purchased with a remaining maturity of three months or less to
                  be cash equivalents.

NOTE 3 - LOAN PAYABLE - SHAREHOLDER:

         On August 30, 2000, the Company borrowed $7,500 from a shareholder of
         the Company.. During the years ended December 31, 2002 and 2001 the
         Company received additional loans from this shareholder in the amount
         of $11,000 and $6,000, respectively. These additional loans also bear
         interest at 6% per annum and as of December 31, 2002 and 2001, interest
         accrued and unpaid aggregated $1,943 and $885, respectively. The due
         date of these loans, which was originally one year from date of
         receipt, have been extended to a date 19 months from November 9, 2001,
         unless the Company is successful in consummating a business acquisition
         at an earlier date.

NOTE 4 - SHAREHOLDERS' EQUITY:

         As of December 31, 2000, the Company issued an aggregate of 3,000,000
         units at a price of $.001 per unit, with each unit consisting of one
         share of common stock and one-third (1/3) of one Class A Redeemable
         Common Stock Purchase Warrant, for cash proceeds of $3,000. Each full
         Class A warrant entitles its holder to purchase one share of common
         stock at $5.00 per share.

         The Company's Registration Statement on Form SB-2, No. 333-45774, (the
         "Registration Statement") was declared effective by the Securities and
         Exchange Commission (the "SEC") on November 9, 2001. The Company
         registered 800,000 shares of its common stock for public sale under the
         Registration Statement, including 200,000 shares issuable upon exercise
         of the Class A warrants underlying the units. On February 14, 2002, the
         Company completed the sale of 600,000 units, pursuant to the
         Registration Statement, at a per unit price of $.03 for gross proceeds
         of $18,000. As a blank check company, in accordance with SEC rules, all
         of the units so sold and the proceeds from such sale are being held in
         escrow.

         If the Company does not complete a business combination prior to May 8,
         2003, such proceeds, and accrued interest, will be returned to the
         investors and the underlying securities canceled. Accordingly, these
         contingently issued shares are not considered outstanding in the
         calculation of earnings per share.

         In April 2002, the Company issued 100,000 shares of its common stock in
         lie of payment of professional fees in the amount of $3,000.


                                     F - 7

<PAGE>

                                   HUNAPU INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                           DECEMBER 31, 2002 AND 2001


NOTE 4 - SHAREHOLDERS' EQUITY (Continued):

              On April 15, 2002, the number of issued and outstanding shares was
              increased by the declaration of a 300% stock dividend (so that
              there would be four shares outstanding for each share previously
              outstanding). The additional 10,800,000 shares have been
              retroactively reflected in calculating earnings (loss) per share
              for all periods presented.



                                     F - 8

<PAGE>



                                   Signatures

         In accordance with Section 13 or 15(d) of the Securities Exchange Act,
the Registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Las Vegas, State of Nevada, on the 7th
day of April, 2003.

                                        HUNAPU INC.


                                        By:       /s/ John C. Francis
                                             ------------------------------
                                                 John C. Francis
                                                 President and Treasurer


         In accordance with the requirements of the Exchange Act, this report
has been signed by the following persons on behalf of the registrant and in the
capacities and on the dates indicated:

Signature                          Title                             Date
---------                          -----                             ----


 /s/ John C. Francis         President, Treasurer                April 7, 2003
------------------------     (Principal Executive
John C. Francis              Officer and Chief
                             Financial Officer) and
                             Chairman of the Board



                                       20
<PAGE>



                                  CERTIFICATION

I, John C. Franis, certify that:

1.   I have reviewed this annual report on Form 10-KSB of Hunapu, Inc.;

2.   Based on my knowledge, this annual report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this annual report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this annual report, fairly present in all material
     respects the financial condition, results of operations and cash flows of
     the registrant as of, and for, the periods presented in this annual report;

4.   I are responsible for establishing and maintaining disclosure controls and
     procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
     registrant and have:

     a)       designed such disclosure controls and procedures to ensure that
              material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within
              those entities, particularly during the period in which this
              annual report is being prepared;

     b)       evaluated the effectiveness of the registrant"s disclosure
              controls and procedures as of a date within 90 days prior to the
              filing date of this annual report (the "Evaluation Date"); and

     c)       presented in this annual report our conclusions about the
              effectiveness of the disclosure controls and procedures based on
              our evaluation as of the Evaluation Date;

5.   I have disclosed, based on our most recent evaluation, to the registrant's
     auditors and the audit committee of registrant's board of directors (or
     persons performing the equivalent functions):

     a)       all significant deficiencies in the design or operation of
              internal controls which could adversely affect the registrant's
              ability to record, process, summarize and report financial data
              and have identified for the registrant"s auditors any material
              weaknesses in internal controls; and

     b)       any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal controls; and


                                       21
<PAGE>

6.   The registrant's other certifying officers and I have indicated in this
     annual report whether there were significant changes in internal controls
     or in other factors that could significantly affect internal controls
     subsequent to the date of our most recent evaluation, including any
     corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: April 7, 2003             By:   /s/ John C. Francis
                                   -----------------------
                                   John C. Francis
                                   President and Treasurer
                                   (Principal Executive and Financial Officer)


                                       22